Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Net Cash Flow (2016 - 2025)

Kiora Pharmaceuticals' Net Cash Flow history spans 11 years, with the latest figure at $3.2 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 279.07% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $4.7 million, up 239.23%, while the annual FY2025 figure was $4.7 million, 239.23% up from the prior year.
  • Net Cash Flow reached $3.2 million in Q4 2025 per KPRX's latest filing, down from $4.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $28.9 million in Q1 2024 to a low of -$24.7 million in Q2 2024.
  • Average Net Cash Flow over 5 years is $379589.9, with a median of -$1.8 million recorded in 2024.
  • The largest YoY upside for Net Cash Flow was 1229.41% in 2024 against a maximum downside of 643.27% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$3.2 million in 2021, then increased by 12.37% to -$2.8 million in 2022, then dropped by 8.55% to -$3.1 million in 2023, then skyrocketed by 42.31% to -$1.8 million in 2024, then surged by 279.07% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Net Cash Flow are $3.2 million (Q4 2025), $4.5 million (Q3 2025), and -$2.9 million (Q2 2025).